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Background: Cisplatin-induced peripheral nerve neurotoxicity (CIPN) is the 
main obstacle in cisplatin treatment. The aim of this study was to compare 
the modulatory effects of N-acetylcysteine (NAC) and progesterone on CIPN, 
because there are scarce literature data on the protective effect of the proge-
sterone on the CIPN.
Materials and methods: Twenty-four rats were divided into four groups: 
control, cisplatin-treated, concomitant cisplatin-treated and NAC-treated, and 
concomitant cisplatin-treated and progesterone-treated. Electron microscopic, 
immunohistochemical, real time polymerase chain reaction and histomorphome-
tric analysis; oxidative/antioxidative markers (MDA/GSH and SOD), neurotoxic/
neuroprotective markers (iNOS/nNOS), inflammatory mediators (TNF-a and 
NF-kB) and BAX were done.
Results: The myelin sheath in the cisplatin-treated group elucidated infolding. 
The myelin was disfigured, degenerated, and extensively split with areas of focal 
loss. The axoplasm was atrophic. Ballooning and vacuolations of the mitochon-
dria with alterations of Remak bundles structures were observed. Fewer of these 
changes were noted in the NAC and progesterone-treated groups. Decrease 
of the antioxidant SOD and GSH (81% and 64%) and increase of the oxidant 
MDA (9 folds), increment of the neurotoxic iNOS (1.9 folds) and decrement of 
the neuroprotective nNOS (64%) and elevation of the inflammatory mediators’ 
TNF-a and NF-kB (8.3 and 11 folds) in the cisplatin-treated group. Increase of 
the antioxidant SOD (1.3 and 2.5 folds) and GSH (120% and 79%) and decrease 
of the oxidant MDA (69% and 88%), decrement of the neurotoxic iNOS (56% 
and 68%) and increment of the neuroprotective nNOS (1.6 and one folds) and 
elevation of the inflammatory mediators’ TNF-a and NF-kB were observed in the 
NAC and progesterone-treated groups, respectively. 
Conclusions: The toxic effect of CIPN might be attributed to either oxidative or 
severe inflammatory stress. Progesterone is efficient in ameliorating these effects; 
however, NAC is better. (Folia Morphol 2018; 77, 2: 234–245)
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INTRODUCTION
Cisplatin is a platinum-derived chemotherapeutic 
drug that is now employed in the treatment of head 
and neck, ovarian, testicular, bladder, colorectal and 
lung cancers [19]. Peripheral neuropathy is one of 
the main complications of chemotherapeutics [40]. 
They range from 10% to 100% depending on the 
anticancer drug [5]. The peripheral neuropathy oc-
curs in about 20% of patients given standard doses 
of chemotherapy and in almost 100% of patients 
treated with high doses [40]. The chemotherapy-
induced peripheral neurotoxicity could be considered 
the main reason for reduction or even stoppage of 
the treatment [52]. The main roles in the mechanism 
of cisplatin-induced cytotoxicity are inflammatory 
cytokines, oxidative stress and DNA damage [10, 30]. 
The mechanisms of cisplatin-induced neurotoxicity 
in the nervous system include inflammation, DNA 
damage, apoptotic cell death, oxidative damage and 
mitochondrial dysfunction [16, 53].
The efficiency of antioxidative treatments on pre-
venting platinum-induced neurotoxicity has been 
established in several studies [2, 9, 55]. Antioxidants 
such as N-acetylcysteine (NAC) [18] have been used 
to reduce this type of toxicity. NAC is the acetylated 
form of L-cysteine, which has a peripheral neuropro-
tective effect through free radical elimination activity; 
cysteine helps in the synthesis of glutathione which is 
a very important natural antioxidant [26]. Progester-
one is a neuroactive steroid that is considered as an 
important neuroprotective and remyelinating agent. 
The probable mechanisms by which progesterone 
produces its neuroprotective effects are debatable; it 
could be either through inhibition of oxidative stress 
and apoptosis or through the decrease of inflamma-
tion [50].
Although many researchers studied the protective 
effect of NAC cisplatin-induced peripheral neurotoxic-
ity (CIPN), its mechanism of action is still debatable. 
Few types of researchers studied the protective ef-
fect of progesterone on the chemotherapy-induced 
peripheral neurotoxicity. 
So, the aim of the present work was to spot the 
deleterious effects of cisplatin on peripheral nerves, 
evaluate the modulatory effects of the progesterone 
on the CIPN and to compare this effect with the effect 
of the NAC on the CIPN. The comparison included the 
structural changes of the sciatic nerve and the pos-
sible mechanism of function of both drugs. The study 
was directed on adult male albino rats using electron 
microscopic, immunohistochemical and oxidative tis-
sue markers histomorphometric analysis and real-time 
polymerase chain reaction (PCR).
MATERIALS AND METHODS
Chemicals
Cisplatin was purchased from Sigma Chemicals 
Corp. (Saint Louis, MO, USA). The used vehicle was 
sterile saline. The rats were injected at a dose of 
2 mg/kg/twice weekly/4 weeks intraperitoneally [31, 
49]. The neurotoxicity induced by such dose is related 
to the direct effect of cisplatin and is not secondary 
to modulation of the drug nephrotoxicity [31]. In 
addition, such dose doesn’t affect the rats’ general 
condition [31]. 
N-acetylcysteine was purchased from Sigma- 
-Aldrich (Saint Louis, MO, USA). The used vehicle 
was sterile saline. The rats were injected at a dose of 
50 mg/kg/daily/4 weeks intraperitoneally [14]. At this 
dose, the NAC is not nephrotoxic. In addition, no ef-
ficacy occurs to cisplatin at such dose [1].
Progesterone was obtained from Algomhuria Pharm. 
and Chem. Co. The used vehicle was peanut oil. The 
rats were injected at a dose of 4 mg/kg/daily/4 weeks 
intraperitoneally [11]. This dose was selected based 
on previously published reports showing that this was 
a relatively low dose that was effective with repeated 
treatment in other models of nerve injury [22, 44, 45].
Animals
Twenty-four Sprague-Dowley adult male albino 
rats weighing 200–220 g were used in the present 
study. The rats were obtained from the animal house, 
Faculty of Medicine, Cairo University, Egypt. They 
were acclimatised to standard laboratory conditions; 
temperature 20°C, allowed free water supply and fed 
ad libitum. All the animals were treated in accordance 
with the international guidelines for the care and 
use of laboratory animals.The study was approved 
by the Ethics Committee, Faculty of Medicine, Cairo 
University (2431/2016). The animals were observed 
twice per day for signs of morbidity and mortality. 
The general toxicological data were recorded includ-
ing the motility, food and water consumption, health 
status and body weight gain. The weights of each 
individual animal were recorded in the beginning and 
at weekly intervals until the end of the experiment.
All animal procedures followed the ethical guide-
lines of experimental animals. Therefore, the study 
had been performed according to the ethical stand-
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ards of the National Institutes of Health guide for 
the care and use of Laboratory Animals (NIH Pub-
lications No. 8023, revised 1978), and we followed 
these guidelines.
Experimental design 
The rats were divided into four groups, 6 rats each: 
1 — control group; 
2 — cisplatin-treated group; 
3 — concomitant cisplatin and NAC-treated group; 
4 — concomitant cisplatin and progesterone-treated 
group.
The animals were sacrificed after 4 weeks. An 
incision was made on the back of both thighs, and 
the sciatic nerves were exposed near the greater sci-
atic foramen. Five small segments, each 5–7 mm in 
length, from each sciatic nerve were cut and kept in 
the fixative in the refrigerator overnight.
Ultrastructural preparations. For electron mi-
croscopy, small pieces of the sciatic nerve from each 
rat were fixed in 2% paraformaldehyde and 2% glu-
taraldehyde solution in 0.1 mol/L phosphate buff-
ered saline (PBS) pH 7.2 and kept in the refrigerator 
overnight, rinsed in 0.1 mol/L PBS and postfixed in 
phosphate-buffered 1% osmium tetroxide. To ob-
tain cross-sections, the nerve samples were oriented 
longitudinally in a flat mold and then embedded in 
resin. Semithin cross-sections were stained with 1% 
toluidine blue and examined by light microscope 
for proper orientation and image analysis of axons 
number. Ultrathin sections (50–60 nm) were stained 
with uranyl acetate and lead citrate. These sections 
were examined and photographed using a Jeom-1400 
transmission electron microscope (JEOL Ltd./Japan 
a Joel), Electron Microscopy Department, Faculty of 
Agriculture, Cairo University, Egypt.
Immunohistochemistry. Five sciatic nerve paraf-
fin blocks were prepared from each rat. The sections 
were dewaxed, dehydrated, and incubated with 3% 
hydrogen peroxide solution for 30 min at room tem-
perature and endogenous peroxidase activity was 
blocked. Then, the sections were washed with distilled 
water, a microwave was utilised for tissue antigen re-
trieval. The buffer solution was cooled and the section 
was taken. The sections were cleaned with distilled 
water and put into PBS for 5 min. After PBS was wiped 
off, the appropriate amount of serum was added into 
the section at room temperature for 30 min. Then, 
the serum was removed. All techniques were done 
according to the manufacturer’s instructions.
Apoptosis (BAX) in sciatic nerve. Five sciatic 
nerve sections from each paraffin block were incu-
bated with anti-rat BAX monoclonal antibody ([E63], 
(ab32503) 1:100) at 4°C overnight. The sections were 
maintained at room temperature for 30 min, and 
rinsed with PBS (pH 7.4) three times, each for 5 min. 
After removal of PBS, the sections were incubated 
with anti-rabbit IgG (ab205718) at 37°C for an hour 
and a half, and rinsed three times with PBS (pH 7.4), 
each for 5 min after removal of PBS.
Inducible nitric oxide synthase (iNOS). Five sci-
atic nerve sections from each paraffin block were 
incubated with a reaction buffer containing primary 
antibody rabbit polyclonal antibody to iNOS (ab15323 
at a dilution of 1:100) for at least 14 h at 4°C. After-
wards the sections were incubated with goat anti-
rabbit IgG H&L (HRP) (ab205718) for 20 min at 37°C. 
Each step was followed by adequately washing with 
PBS (0.1 mol/L, pH 7.2–7.4).  
Tumour necrotic factor alpha (TNF-a). Five sci-
atic nerve sections from each paraffin block were 
incubated overnight at 4°C with the following primary 
antibody rabbit polyclonal to TNF-a (ab66579 diluted 
1:500). The primary antibody was diluted in PBS, sec-
tions were subsequently incubated for 1 hour at room 
temperature with secondary with goat anti-rabbit IgG 
H&L (HRP) (ab205718) in PBS containing 0.3% Triton 
X-100 and 1% body surface area. 
3,3’-diaminobenzidine (DAB) was applied as the 
chromogen, and all the previous immunohistochemi-
cal sections were visualised with DAB (Sigma, Aldrich.) 
and observed under a microscope to visualise the de-
velopment of colour. Following rinsing with distilled 
water and running water successively. The sections 
were counterstained with haematoxylin, permeabi-
lised with xylene, mounted with resin and treated 
with a decreasing ethanol series. All antibodies were 
purchased from Abcam, United Kingdom. Negative 
control sections were performed using the same 
previous procedure except that the primary antibody 
was replaced by non-immune mouse serum immu-
noreactivity. The iNOS positive control is lung; Raw 
264.7 whole cell lysate + PMA + LPS + Brefeldin A. 
The TNF-a and BAX positive control are the human 
mammary cancer. The TNF-a antibody gave a posi-
tive signal in the following LPS stimulated lysates: 
THP1, Raw264.7 IF/ICC: PMA/Befreldin/LPS treated 
RAW246.7 cell line.
Oxidative/antioxidative marker. Five sciatic nerve 
sections from each rat:
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 — Oxidative stress marker: Malondialdehyde (MDA) 
was measured according to the manufacturer’s 
instructions. 100 mg of tissue was homogenised 
in 1 mL PBS, pH 7.0 with micropestle in a micro-
tube. 20% trichloroacetic acid (TCA) was added 
to sciatic nerve tissue homogenate to precipitate 
the protein and centrifuged. Supernatants were 
collected and thiobarbituric acid (TBA) solution 
was added to the supernatants. After boiling for 
10 min in water bath, the absorbance was meas-
ured. The concentration of MDA was calculated 
using the standard curve.
 — Anti-oxidative stress markers: The techniques 
were done according to the manufacturer’s in-
structions. The measurement of glutathione (GSH) 
is based on the reduction of 5, 5 dithiobis (2-ni-
trobenzoic acid) (DTNB) with reduced glutathione 
to produce a yellow compound. The reduced chro-
mogen is directly proportional to GSH concentra-
tion and its absorbance is measured at 405 nm by 
using a commercial kit (Biodiagnostic, Egypt) [39]. 
GSH activity was determined by the procedure 
of Carlberg and Mannervik 1985. The assay solu-
tion contained 10% bovine serum albumin (BSA), 
50 mM potassium phosphate buffer (pH 7.6), 
2 mM nicotinamide adenine dinucleoticle phos-
phate (NADPH) and 20 mM oxidised glutathione. 
Absorbance at 340 nm was recorded at a tempera-
ture of 250oC. The activity was calculated using 
the molar coefficient for NADPH of 6.22 µmol–1 
× cm–1 and expressed in U/g of tissue.
The superoxide dismutase (SOD) activity in tissue 
homogenate was measured by the inhibition of ni-
troblue tetrazolium reduction by O2– generated by the 
xanthine/xanthine oxidase system. One SOD activity 
unit was defined as the enzyme amount causing 50% 
inhibition in 1 mL reaction solution per milligram tissue 
protein and the result was expressed as U/mg protein.
Image analysis and morphometric measure-
ments. The area per cent of immune expression 
of BAX, iNOS and TNF-a was done using Leica LAS 
V3.8 image analyser computer system (Switzerland). 
Counting of axons was done in the toluidine blue 
sections. The measurements were obtained by an 
independent blinded observer, who didn’t know the 
experimental design. In each chosen field, the sciatic 
nerve was enclosed inside the standard measuring 
frame. The data was obtained in ten non-overlapping 
fields per specimen at a magnification of 400. Im-
ages were captured live on the screen from sections 
under a light microscope (Olympus Bx-40, Olympus 
Optical Co. Ltd., Japan) with an affixed video camera 
(Panasonic colour CCTV camera, Matsushita Com-
munication Industrial Co. Ltd., Japan).
Gene expression of nuclear factor (NF-kB 65)  
and neuronal nitric oxide synthase (nNOS)  
by the real time PCR
Total RNA extraction. Total RNA was extracted 
from sciatic nerve tissues using the TRIzol method ac-
cording to the manufacturer’s protocol. In brief, RNA 
was extracted by homogenisation in TRIzol reagent 
(Invitrogen, Life Technologies, USA). The sciatic nerve 
tissue homogenate was then incubated for 5 min at 
room temperature. A 1:5 volume of chloroform was 
added, and the tube was vortexed and centrifuged 
at 12,000 g for 15 min. The aqueous phase was 
isolated, and the total RNA was precipitated with 
absolute ethanol. After centrifugation and washing, 
the total RNA was finally eluted in 20 µL of the RNase- 
-free water. The RNA concentrations and purity were 
measured with an ultraviolet spectrophotometer.
Complementary DNA (cDNA) synthesis. The 
cDNA was synthesized from 1 µg RNA using Super-
script III First-Strand Synthesis System as described 
in the manufacturer’s protocol (Invitrogen, Life Tech-
nologies). In brief, 1 µg of total RNA was mixed with 
50 µM oligo (DT) 20, 50 ng/µL random primers, and 
10 mM dNTP mix in a total volume of 10 µL. The 
mixture was incubated at 56°C for 5 min and then 
placed on ice for 3 min. The reverse transcriptase 
master mix containing 2 µL of 10 × real time buffer, 
4 µL of 25 mM MgCl2, 2 µL of 0.1 M DTT, and 1 µL 
of SuperScript® III real time (200 U/µL) was added to 
the mixture and was incubated at 25°C for 10 min 
followed by 50 min at 50°C.
Real-time (RT) quantitative PCR. The relative 
abundance of mRNA species was assessed using the 
SYBR Green method on an ABI prism 7500 sequence 
detector system (Applied Biosystems, Foster City, CA). 
PCR primers were designed with Gene Runner Soft-
ware (Hasting Software, Inc., Hasting, NY, USA) from 
RNA sequences from Gen Bank. All primer sets had 
a calculated annealing temperature of 60°C. Quantita-
tive RT-PCR was performed in a 25-µL reaction volume 
consisting of 2X SYBR Green PCR Master Mix (Applied 
Biosystems), 900 nM of each primer and 2–3 µL of 
cDNA. Amplification conditions were 2 min at 50°, 
10 min at 95° and 40 cycles of denaturation for 15 s 
and annealing/extension at 60° for 10 min. Data 
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from real-time assays were calculated using the v1·7 
Sequence Detection Software from PE Biosystems 
(Foster City, CA, USA). Relative expression of studied 
gene mRNA was calculated using the comparative Ct 
method. All values were normalised to the beta actin 
gene and reported as fold change over background 
levels detected in diseases group (Table 1).
Statistical analysis
Statistical analysis was performed using statistical 
package for the social sciences (SPSS) version 21.0 
(IBM Corporation, Somers, NY, USA) statistical soft-
ware. The data were expressed as means ± standard 
deviation (SD). Statistical evaluation was done using 
one-way analysis of variance (ANOVA) followed by 
Bonferroni pairwise comparisons. Significance was 
considered when the p-value was less than 0.05. 
The percentage of increase or decrease (differ-
ence) of all study parameters were calculated per the 
following formula: Percentage of difference = (Mean 
difference value between two groups)/(Value of the 
compared group) × 100.
RESULTS
The general toxicological data (Table 2)
No evidence of general toxicity was observed 
among the studied groups. The motility, food and 
water consumption and health status were relatively 
good.
The mean body weight of the cisplatin-treated 
group was 8% lower than that of the control group 
at the end of the 1st week, and the weight was 19% 
lower at the end of the 4th week. 
Compared to that of the control group, the mean 
body weight of the NAC and progesterone-treated 
groups were 3% and 5% lower than that of the 
control group at the end of the 1st week, and the 
weights were 16% and 18% lower at the end of 
the 4th week.
Semithin sections
The number of axons of the sciatic nerve and the 
myelin sheath was affected in the cisplatin-treated 
group. Although the findings in the NAC-treated 
group were near to that of the control group, the 
number in the progesterone-treated group was away 
from that of the control group (Fig. 1).
Ultrastructural observation
The sciatic nerve of the control group showed 
myelinated nerve fibres. The axoplasm contains 
intact mitochondria and the endoneurium inter-
spersed between axons. Schwann cells and regu-
lar unmyelinated axons in Remak bundles are also 
observed (Fig. 2). 
Table 2. The mean of the body weight study in the different experimental groups
Control Cisplatin-treated NAC-treated Progesterone-treated P 
End of the 1st week 210.0 ± 7.1 192.8 ± 5.6 202.3 ± 8.3 198.2 ± 6.8 0.000*
End of the 4th week 232.3 ± 5.6 186.0 ± 2.1 194.0 ± 4.6 189.8 ± 1.8 0.000*
p value > 0.05 is significant; NAC — N-acetylcysteine
Table 1. The primers sequence for all studied genes
Gene Primers sequence
NF-kB Forward primer: 5’-CATTGAGGTGTATTTCACGG-3’  
Reverse primer: 5’-GGCAAGTGGCCATTGTGTTC-3’
nNOS Forward: 5’-CCGTTTCTCCTGGCTCAGTTTA-3’ 
Reverse: 5’-CCCCAATACC ACATCATCCAT-3’
NF-kB — gene expression of nuclear factor; nNOS — neuronal nitric oxide synthase
Figure 1. Semithin sections of the sciatic nerve showing the 
axons (A) and myelin sheath (M) in different groups (Toluidine 
blue ×1000); a. The control group; b. Decrease number of axons 
with degeneration and focal loss of myelin sheath in the cisplatin-
treated rat; c. Normal axons and myelin in the N-acetylcysteine 
and progesterone-treated rats; d. Decreased the number of axons 
in the progesterone-treated rat. Note: capillary (C).
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Figure 4. Electron photomicrograph of the sciatic nerve in the 
NAC and progesterone-treated rats; a. Myelinated nerve fibers (M) 
with slight infolding (curved arrow), unmyelinated axons in Remak 
bundles (R) with thin and loose myelin sheath, suggestive of remy-
elination (arrow). Slight vacuolation (V) of the axoplasm (Ax) sepa-
rated by endoneurium (En). Note intact mitochondria (arrowheads) 
in the N-acetylcysteine-treated rat (TEM ×5000); b. Myelinated 
nerve fibers (M) with infolding (arrows), unmyelinated axons in 
Remak bundles (R) with thin and loose myelin sheath, suggestive 
of remyelination (curved arrows). Vacuolations (arrowhead) of the 
axoplasm (Ax) in the progesterone-treated rat (TEM ×3000).
The myelin sheath in the cisplatin-treated group 
elucidated infolding. The myelin was disfigured, 
degenerated, and extensively split with areas of 
focal loss. The axoplasm was atrophic. Balloon-
ing and vacuolations of the mitochondria with 
alterations of Remak bundles structures (lack of 
Schwann cell cytoplasm between axons) were also 
observed (Fig. 3).
Fewer of the previously mentioned effects were 
noted in the NAC and progesterone-treated groups 
suggesting a protective role of both drugs. Thin and 
loose myelin sheath was observed in both groups 
suggestive of remyelination. Better findings were ob-
served in the NAC-treated group compared to that of 
the progesterone-treated group. Myelin infolding and 
vacuolations of the axoplasm were more extensive in 
the progesterone-treated group compared to that of 
the NAC-treated group (Fig. 4).
Immunohistochemical studies
The immunoreaction of BAX, iNOS, and TNF-a 
is cytoplasmic. The reaction in the different studied 
groups was strongly positive in the cisplatin-treated 
group when compared to that of the control group. 
The intensity of the reaction decreased in the NAC 
and progesterone-treated groups (Figs. 5–7).
Histomorphometric study (Tables 3–6)
BAX, iNOS and TNF-a immunoexpression 
(Table 3). The mean area per cent of BAX immunoex-
pression of the cisplatin-treated group was 1.3-fold 
significantly higher than that of the control group.
Figure 2. Electron photomicrograph of the sciatic nerve of the 
control group; a. Myelinated nerve fibers (*), axoplasm (ax) and 
endoneurium (EN) interspersed between axons. Note Schwann cell 
with its euchromatic nucleus (N) and regular unmyelinated axons 
in Remak bundles (R) (TEM ×5000); b. Myelinated nerve fibers 
(M), axoplasm (Ax), mitochondria (arrowheads) and endoneurium 
(EN) (TEM ×8000).
Figure 3. Electron photomicrograph of the sciatic nerve in the 
cisplatin-treated rats; a. Disfigured myelinated nerve fiber (M), 
degenerated myelin (arrows) and vacuolated (vac) axoplasm 
(TEM ×6000); b. An extensive myelin splitting with focal loss of 
myelin (M) into an inner part that surrounds the axoplasm (Ax) and 
outer part. The space between the two parts contains fragmented 
myelin. Note: excessive infolding of myelin (arrowheads), axonal 
separation and loss of endoneurium (en) (TEM ×4000); c. Exten-
sive myelin (M) splitting with focal thickening of degenerated my-
elin sheath (arrowheads). Atrophy of the axoplasm (AX) with their 
vacuolations (arrows). Note alterations of Remak bundle (R) (lack 
of Schwann cell cytoplasm between axons) (TEM ×5000); d. Ex-
tensive myelin splitting seeming to entrap the adjacent axon (EN), 
focal loss of myelin (arrows) with vacuolation of the axoplasm (*). 
Note abnormal ballooning and vacuolation of the mitochondria (ar-
rowheads) (TEM ×6000).
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The mean area per cent of the immunoreactions 
of iNOS the cisplatin-treated group was 1.7-fold sig-
nificantly higher than that of the control group. Con-
trary, the area per cent in the NAC and progesterone-
treated groups were 56% and 68% significantly lower 
than that of the cisplatin-treated group. 
The mean area per cent of the immunoreaction 
of TNF-a of the cisplatin-treated group was 8.3-folds 
significantly higher than that of the control group. 
Although the area per cent’s in the NAC and proges-
terone-treated groups were 55% and 47% signifi-
cantly lower than that of the cisplatin-treated group, 
theses per cent didn’t return to the control level as 
these percentages were 31% and 39% higher than 
that of the control group.
Oxidative/antioxidative markers (Table 4). The 
mean value of MDA of the cisplatin-treated group was 
Figure 6. Photomicrograph of the sciatic nerve sections showing 
the immunoreactivity to inducible nitric oxide synthase (iNOS,  
arrows) in different groups (iNOS ×400); a. Weak immunoreaction 
reaction in the control group; b. Strong immunoreaction in the 
cisplatin-treated rat; c, d. Weak immunoreaction reaction in the 
N-acetylcysteine and progesterone-treated rats.
Figure 7. Photomicrograph of the sciatic nerve sections showing 
the immunoreactivity to tumour necrotic factor alpha (TNF-a,  
arrows) in different groups (TNF-a ×400); a. Weak immunoreaction 
reaction in the control group; b. Strong immunoreaction in the 
cisplatin-treated rat; c, d. Weak immunoreaction reaction in the 
N-acetylcysteine and progesterone-treated rats.
Figure 5. Photomicrograph of the sciatic nerve sections showing the 
immunoreactivity to bax (arrows) in different groups (BAX ×400); 
a. Weak immunoreaction reaction in the control group; b. Strong im-
munoreaction in the cisplatin-treated rat; c, d. Weak immunoreaction 
reaction in the N-acetylcysteine and progesterone-treated rats.
Table 3. The mean area per cent of BAX, inducible nitric oxide synthase (iNOS), and tumour necrotic factor alpha (TNF-a) immunoex-
pression in the different experimental groups
Groups iNOS TNF-a BAX
Control 1.13 ± 0.19 0.76 ± 0.18 1.31 ± 0.412
Cisplatin-treated 3.13 ± 1.43+#$ 7.09 ± 0.79+#$ 3.01 ± 1.02+
NAC-treated 1.38 ± 0.21* 3.12 ± 1.04+* 1.70 ± 0.34
Progesterone-treated 0.99 ± 0.12* 3.73 ± 1.30+* 1.70 ± 0.34
NAC — N-acetylcysteine; +p < 0.05 — significant difference compared to that of the control group; *p < 0.05 — significant difference compared to that of the cisplatin-treated group; 
#p < 0.05 — significant difference compared to that of the NAC-treated group; $p < 0.05 — significant difference compared to that of the progesterone-treated group
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significantly nine folds higher than that of the control 
group. The MDA levels in the NAC and progesterone-
treated groups were 69% and 88% significantly lower 
than that of the cisplatin-treated group.
The mean value of SOD of the cisplatin-treated group 
was significantly 81% lower than that of the control 
group. Although the SOD levels in the NAC and proges-
terone-treated groups were significantly 1.3 and 2.5 folds 
higher than that of the cisplatin-treated group, these 
levels didn’t return to the control level as these levels were 
57% and 33% lower than that of the control group. The 
level of the SOD in the progesterone-treated group was 
about 54% higher than that of the NAC-treated group.
The mean value of the GSH of the cisplatin-treated 
group was significantly 64% lower than that of the 
control group. Although the GSH levels in the NAC 
and progesterone-treated groups were 120% and 
79% higher than that of the cisplatin-treated group, 
these levels didn’t return to the control level as these 
levels were 20% and 36% lower than that of the 
control group. The level of the GSH in the progester-
one-treated group was 19% lower than that of the 
NAC-treated group. 
NF-kB and nNOS (Table 5). The mean value of 
NF-kB of the cisplatin-treated group was significantly 
11 folds higher than that of the control group. Al-
though the NF-kB levels in the NAC and progesterone-
treated groups were significantly 68% and 48% lower 
than that of the cisplatin-treated group, these levels 
didn’t return to the control level as these levels were 
2.8 and 5.1 folds higher than that of the control 
group. The level of NF-kB in the progesterone-treated 
group was 62% higher than that of the NAC-treated 
group. 
The mean value of nNOS of the cisplatin-treated 
group was significantly 64% lower than that of the 
control group. The level in the NAC-treated group 
was 1.6 folds higher than that of the cisplatin-treated 
group.
Axons number (Table 6). The mean number of 
axons of the sciatic in the cisplatin-treated group 
was significantly 50% lower than that of the control 
group. The mean number of axons in the NAC-treated 
group was like that the control group. In contrary, 
the axons number in the progesterone-treated group 







Control 1.04 ± 0.18 2.90 ± 0.23 58.55 ± 2.02
Cisplatin-treated 10.33 ± 2.57+#$ 0.54 ± 0.24+#$ 20.88 ± 1.74+#$
NAC-treated 3.20 ± 1.31* 1.26 ± 0.24+*$ 46.40 ± 9.34+*$
Progesterone-treated 1.26 ± 0.24* 1.94 ± 0.16+*# 37.58 ± 6.91+*#
GSH — glutathione; MDA — malondialdehyde; NAC — N-acetylcysteine; SOD — superoxide dismutase; +p < 0.05 — significant difference compared to that of the control group;  
*p < 0.05 — significant difference compared to that of the cisplatin-treated group; #p < 0.05 — significant difference compared to that of the NAC-treated group; $p < 0.05 — significant 
difference compared to that of the progesterone-treated group
Table 5. The mean values ± standard deviation of gene  
expression of nuclear factor (NF-kB) and neuronal nitric oxide 
synthase (nNOS) in the different experimental groups 
Groups NF-kB nNOS
Control 1.01 ± 0.01 1.00 ± 0.00
Cisplatin-treated 12.12 ± 2.47+#$ 0.36 ± 0.26+#
NAC-treated 3.86 ± 0.72+*$ 0.94 ± 0.30*
Progesterone-treated 6.25 ± 0.71+*# 0.71 ± 0.26
NAC — N-acetylcysteine; +p < 0.05 — significant difference compared to that of the 
control group; *p < 0.05 — significant difference compared to that of the cisplatin-
-treated group; #p < 0.05 — significant difference compared to that of the NAC-treated 
group; $p < 0.05 — significant difference compared to that of the progesterone-treated 
group
Table 6. The mean values ± standard deviation (SD) of the 
number of axons in the different experimental groups 
Groups Mean ± SD
Control 125.00 ± 12.91*$
Cisplatin-treated 61.25 ± 8.54+#
NAC-treated 126.25 ± 12.50*$
Progesterone-treated 80.00 ± 8.16+
# NAC — N-acetylcysteine; +p < 0.05 — significant difference compared to that of 
the control group; *p < 0.05 — significant difference compared to that of the cisplatin-
-treated group; #p < 0.05 — significant difference compared to that of the NAC-treated 
group; $p < 0.05 — significant difference compared to that of the progesterone-treated 
group
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was 44% lower than that of the control and NAC-
-treated groups.
DISCUSSION
Cisplatin-induced sciatic nerve damage in the rat 
model has been proven in many studies [34]. Cisplatin 
has a molecular affinity for the peripheral nerves as 
they lack the vascular and lymphatic barriers, which 
make them more susceptible to the precipitation of 
the cisplatin debris [25, 41]. In addition, the mamma-
lian nerves are known to be more susceptible to oxida-
tive stress due to their high content of phospholipids 
and mitochondria-rich axoplasm [35]. Moreover, their 
cellular antioxidant defences are weak [35].
Cisplatin administration triggered many patho-
logical changes in the myelin sheath in the form of 
infolding, extensive splitting, and focal myelin loss. 
The myelin sheath is the most vulnerable part to 
neuronal injury by chemotherapy [4]. 
The mechanisms underlying CIPN are incompletely 
understood [7]. The first possible studied mechanism 
was the reduction in the tissue antioxidants (SOD 
and GSH) and the increase in the tissue oxidants 
(MDA), which were observed in the cisplatin-treated 
group. The shift in the balance between oxidants 
and antioxidants in the favour of oxidants is termed 
“oxidative stress” [6]. The oxidative stress induced by 
cisplatin causes deleterious distortion of the nervous 
tissue which might reach demyelination or even my-
elin degeneration. Furthermore, during the ongoing 
process of the release of the nitric oxide (NO) and 
reactive oxygen species (ROS), the tissue antioxidants 
are depleted [13], which in turn results in axonal injury 
[17]. Finally, the total number of axons decreased in 
this group.
Mitochondrial dysfunction was the second pos-
sible studied mechanism of the CIPN [10]. The vacu-
olated mitochondria detected in the cisplatin-treated 
group might be due to their damage by the free 
radicals. Mitochondrial impairment plays a chief 
role in nervous tissue toxicity [36]. The precipitation 
of distorted-mitochondria results in more oxidative 
stress, and more damage to peripheral nerve and 
neurodegeneration [48].
The third possible studied mechanism of the CIPN 
was the disturbance of the neurotoxic/neuroprotec-
tive mechanism (iNOS/nNOS). An increase in the 
values of the neurotoxic iNOS and decrease in the 
values of the neuroprotective nNOS was observed in 
the cisplatin-treated group. NO could be considered 
as a double-agent as regard to its neurotoxic and 
neuroprotective role [8]. The ROS induced by cisplatin 
resulted in an increase in the values of the neurotoxic 
iNOS and a decrease in the values of the neuropro-
tective nNOS [12]. The neurotoxic effect of the iNOS 
is via caspase-dependent and caspase-independent 
mechanisms [12], while the neuroprotective effect of 
the nNOS is via the release of the hypoxia-inducible 
factor-1, the transcriptional activator of several genes 
which are involved in the neuroprotection [27].
Inflammation was the fourth studied mechanism 
of the CIPN. Many proinflammatory mediators such as 
TNF-a and NF-kB were shown to be involved in cispl-
atin-induced renal toxicity [47] and in cisplatin-induced 
vestibular-toxicity [29]. In our study, the proinflamma-
tory mediators NF-kB and TNF-a were highly elevated 
in the cisplatin-treated group. The proinflammatory 
cytokines (TNF-a) is upregulated early and transiently at 
the site of nerve injury and is considered as an initiator 
of local inflammatory responses [20].
The last possible studied mechanism of the CIPN 
was the apoptosis. The mean area per cent of BAX 
gene immunoexpression in the cisplatin-treated 
group was 1.3-fold higher than that of the control 
group. The protein encoded by this gene belongs 
to the BCL2 protein family. This protein functions 
as an apoptotic activator [24]. Cisplatin-mediated 
cytotoxicity creates a downstream effect on a vari-
ety of molecular factors including activation of p53 
and subsequent modulation of Bcl-2 family proteins 
including the pro-apoptotic protein s BAX [54]. Cis-
platin release cytochrome c from mitochondria that 
translocate BAX [21]. 
Fewer of the previously mentioned pathological 
findings were noted in the NAC and progesterone-
treated groups suggesting a protective role of both 
drugs. The structure of the mitochondria in the axo-
plasm and the myelin sheath were well preserved in 
both groups. In addition, the myelin sheath in both 
groups was thin and loose that suggest remyelination. 
The condition of the sciatic nerve was much better in 
the NAC-treated group. 
Concerning the first possible studied mechanism 
of the CIPN, both NAC and progesterone ameliorated 
the oxidative stress-induced by cisplatin. A significant 
reduction of MDA and a significant elevation of SOD 
and GSH were observed with both drugs. This path-
way allows partial protection against the CIPN as the 
level of all was away from that of the control group. 
The main way of action of the NAC was through the 
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elevation of the GSH as the NAC is a precursor for GSH 
and aids in its synthesis [23, 32], while the main way 
of action of progesterone was through the elevation 
of SOD as progesterone increases the release of SOD 
[38]. A non-significant difference between NAC and 
progesterone concerning their way of reduction of 
MDA was detected. It was postulated that the NAC 
interferes with the interaction of ROS with proteins, 
lipids, and DNA by forming complexes with cisplatin; 
handicapping formation of free radicals and ROS [46]. 
Concerning the second studied mechanism of the 
CIPN, the structure of the mitochondria in the axo-
plasm was well preserved in the use of both NAC and 
progesterone. The ability of the NAC and progester-
one to restore and preserve the normal mitochondrial 
function was proved in many studies [3, 37, 42]. The 
normal mitochondrial function is important as the 
mitochondrial dysfunction is the main cause of redox 
imbalance and apoptosis in peripheral neurons [21].
Concerning the third studied mechanism of the 
CIPN, improvement of the disturbance of the neuro-
toxic/neuroprotective mechanism (iNOS/nNOS) was 
observed with the use of the NAC and progesterone. 
The value of neurotoxic iNOS decreased, while the 
value of the neuroprotective nNOS increased in both 
groups. The iNOS/nNOS pathway appears to be an 
excellent way of both drugs in the protection of the 
nerve against the CIPN. A non-significant difference 
in both iNOS and nNOS was observed on comparing 
the two groups with each other, and when compar-
ing each group to that of the control group. Some 
studies proved the role of progesterone in inhibition 
of the NO production [15].
Concerning the role of inflammation in the mech-
anism of the CIPN, the levels of TNF-a and NF-kB 
in the NAC and progesterone-treated groups were 
significantly lower. However, the levels both mark-
ers were still higher than that of the control group, 
which reflects the minor role of this pathway. The 
anti-inflammatory role of the NAC seems to be supe-
rior on that of the progesterone as the NF-kB in the 
progesterone-treated group was 62% higher than 
that of the NAC-treated group. The anti-inflammatory 
role of the NAC might be through stabilisation of mi-
tochondria, as the ROS released in mitochondria had 
been reported to trigger the production of proinflam-
matory cytokines [28]. This hypothesis is supported 
by the intact mitochondria in the NAC-treated group. 
In addition, NAC can suppress NF-kB-activated path-
ways in which cytokine cascades are induced [33]. 
On the other hand, progesterone seems to suppress 
the inflammatory process by inhibiting the release of 
cytokine and by handicapping immune cell activation 
and migration [51].
A non-significant difference of the area per cent 
of BAX was observed in the NAC and progesterone-
treated groups. Few types of research reported the 
anti-apoptotic effect of the NAC through reduction 
of BAX [43]. 
CONCLUSIONS
In conclusion, CIPN can be attenuated by concomi-
tant use of the NAC or progesterone with cisplatin. 
The protective effect of the NAC is superior to that 
of the progesterone as the main number of axons 
of the sciatic nerve was lower in the progesterone-
-treated group. The main way of action of both drugs 
is through oxidative/antioxidative markers (MDA/GSH 
and SOD), neurotoxic/neuroprotective mechanism 
(iNOS/nNOS) and through inhibition of the inflam-
matory mediators (TNF-a and NF-kB).
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